623 related articles for article (PubMed ID: 29271940)
41. Off-tumor target--beneficial site for antiangiogenic cancer therapy?
Cao Y
Nat Rev Clin Oncol; 2010 Oct; 7(10):604-8. PubMed ID: 20683436
[TBL] [Abstract][Full Text] [Related]
42. Assessing the in vivo efficacy of biologic antiangiogenic therapies.
Wilson PM; LaBonte MJ; Lenz HJ
Cancer Chemother Pharmacol; 2013 Jan; 71(1):1-12. PubMed ID: 23053262
[TBL] [Abstract][Full Text] [Related]
43. Sialic acid as a target for the development of novel antiangiogenic strategies.
Chiodelli P; Urbinati C; Paiardi G; Monti E; Rusnati M
Future Med Chem; 2018 Dec; 10(24):2835-2854. PubMed ID: 30539670
[TBL] [Abstract][Full Text] [Related]
44. Inhibition of CYP4A by a novel flavonoid FLA-16 prolongs survival and normalizes tumor vasculature in glioma.
Wang C; Li Y; Chen H; Zhang J; Zhang J; Qin T; Duan C; Chen X; Liu Y; Zhou X; Yang J
Cancer Lett; 2017 Aug; 402():131-141. PubMed ID: 28602979
[TBL] [Abstract][Full Text] [Related]
45. Antiangiogenic agents in cancer therapy.
Lenz HJ
Oncology (Williston Park); 2005 Apr; 19(4 Suppl 3):17-25. PubMed ID: 15934499
[TBL] [Abstract][Full Text] [Related]
46. Antiangiogenic therapy: a novel approach to overcome tumor hypoxia.
Peng F; Chen M
Chin J Cancer; 2010 Aug; 29(8):715-20. PubMed ID: 20663317
[TBL] [Abstract][Full Text] [Related]
47. Flavonoids: recent advances as anticancer drugs.
Liu HL; Jiang WB; Xie MX
Recent Pat Anticancer Drug Discov; 2010 Jun; 5(2):152-64. PubMed ID: 20088766
[TBL] [Abstract][Full Text] [Related]
48. Classical and non-classical proangiogenic factors as a target of antiangiogenic therapy in tumor microenvironment.
Marech I; Leporini C; Ammendola M; Porcelli M; Gadaleta CD; Russo E; De Sarro G; Ranieri G
Cancer Lett; 2016 Sep; 380(1):216-26. PubMed ID: 26238184
[TBL] [Abstract][Full Text] [Related]
49. Synopsis of angiogenesis inhibitors in oncology.
Ellis LM; Liu W; Fan F; Jung YD; Reinmuth N; Stoeltzing O; Takeda A; Akagi M; Parikh AA; Ahmad S
Oncology (Williston Park); 2002 May; 16(5 Suppl 4):14-22. PubMed ID: 12102576
[TBL] [Abstract][Full Text] [Related]
50. Adrenomedullin as a therapeutic target in angiogenesis.
Deville JL; Salas S; Figarella-Branger D; Ouafik L; Daniel L
Expert Opin Ther Targets; 2010 Oct; 14(10):1059-72. PubMed ID: 20846006
[TBL] [Abstract][Full Text] [Related]
51. Natural Products with Antiangiogenic and Antivasculogenic Mimicry Activity.
Guan YY; Luan X; Lu Q; Liu YR; Sun P; Zhao M; Chen HZ; Fang C
Mini Rev Med Chem; 2016; 16(16):1290-1302. PubMed ID: 26864555
[TBL] [Abstract][Full Text] [Related]
52. Functional evaluation of synthetic flavonoids and chalcones for potential antiviral and anticancer properties.
Mateeva N; Eyunni SVK; Redda KK; Ononuju U; Hansberry TD; Aikens C; Nag A
Bioorg Med Chem Lett; 2017 Jun; 27(11):2350-2356. PubMed ID: 28442256
[TBL] [Abstract][Full Text] [Related]
53. Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer.
Quesada AR; Medina MA; Alba E
Bioessays; 2007 Nov; 29(11):1159-68. PubMed ID: 17935210
[TBL] [Abstract][Full Text] [Related]
54. Antiangiogenic therapy at a crossroads: clinical trial results and future directions.
Ellis LM
J Clin Oncol; 2003 Dec; 21(23 Suppl):281s-283s. PubMed ID: 14645411
[No Abstract] [Full Text] [Related]
55. Antiangiogenic drugs currently used for colorectal cancer: what other pathways can we target to prolong responses?
Abbadessa G; Vogiatzi P; Rimassa L; Claudio PP
Drug News Perspect; 2007 Jun; 20(5):307-13. PubMed ID: 17878958
[TBL] [Abstract][Full Text] [Related]
56. Antiangiogenic therapy for cancer: an update.
Shojaei F; Ferrara N
Cancer J; 2007; 13(6):345-8. PubMed ID: 18032969
[TBL] [Abstract][Full Text] [Related]
57. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
[TBL] [Abstract][Full Text] [Related]
58. Antiangiogenesis and vascular disrupting agents in cancer: circumventing resistance and augmenting their therapeutic utility.
Close A
Future Med Chem; 2016; 8(4):443-62. PubMed ID: 26933926
[TBL] [Abstract][Full Text] [Related]
59. AngiomiRs: MicroRNAs driving angiogenesis in cancer (Review).
Salinas-Vera YM; Marchat LA; Gallardo-Rincón D; Ruiz-García E; Astudillo-De La Vega H; Echavarría-Zepeda R; López-Camarillo C
Int J Mol Med; 2019 Feb; 43(2):657-670. PubMed ID: 30483765
[TBL] [Abstract][Full Text] [Related]
60. Vascular remodeling and clinical resistance to antiangiogenic cancer therapy.
Glade Bender J; Cooney EM; Kandel JJ; Yamashiro DJ
Drug Resist Updat; 2004; 7(4-5):289-300. PubMed ID: 15533766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]